TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17005948

Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy with immediate lymphadenectomy
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Postoperative observation of regional lymph nodes with lymphadenectomy if nodal relapse occurred
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy (tumor-positive sentinel nodes)
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy (tumor-negative sentinel nodes)
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Immediate lymphadenectomy among patients with nodal metastases
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Delayed lymphadenectomy among patients with nodal metastases
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Biopsy group
Number of subjects: 1269
Study: 14585899

Group type: EXPERIMENTAL
Intervention: CO(2)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 415
Study: 10768622

Group type: EXPERIMENTAL
Intervention: Probable DLB
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Visual hallucinations in DLB (n = 18)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Television misidentifications in DLB (n = 5)
Number of subjects: 24
Study: 8807172

Group type: EXPERIMENTAL
Intervention: 0.1 microgram.kg‐1.min‐1 PGE1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 lidocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.05 microgram.kg‐1.min‐1 PGE1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 80
Study: 1533767

Group type: EXPERIMENTAL
Intervention: 8-33 ANP in 5% mannitol (0.7 microgram/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8-33 ANP in 5% mannitol (1.05 micrograms/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8-33 ANP in 5% mannitol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (5% mannitol)
Number of subjects: 12
Study: 30141289

Group type: EXPERIMENTAL
Intervention: Warming needling combined with Zhuyu Tongluo Xuebi decoction
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ciloprost (100 mg, twice a day)
Number of subjects: 96
Study: 26318400

Group type: EXPERIMENTAL
Intervention: Single-use energy device (Ligasure 5-mm Blunt Tip LF1537 with the Force Triad generator)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reusable bipolar forceps (RoBi 5 mm) and monopolar scissors using the same Covidien Force Triad generator
Number of subjects: 46
Study: 24501094

Group type: EXPERIMENTAL
Intervention: PACAP38 (10 pmol/kg/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: vasoactive intestinal polypeptide (8 pmol/kg/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PACAP38
Number of subjects: 24

Group type: COMPARATOR
Intervention: vasoactive intestinal polypeptide
Number of subjects: 24
Study: 24377889

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine (2 mg)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 20525225

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 35144
Study: 18983695

Group type: EXPERIMENTAL
Intervention: Intensive dose of renal replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less-intensive dose of renal replacement therapy
Number of subjects: 0
Study: 16896036

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 mug/d in the form of selenomethionine)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 537
Study: 14620915

Group type: EXPERIMENTAL
Intervention: MUC1 detection in breast cancer tissue using three anti-MUC1 core protein MAbs (C595, HMFG2, SM3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Serum MUC1 levels measurement through Cancer Associated Serum Antigen test and CA15-3 test
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Measurement of IgG and IgM anti-MUC1 antibodies
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Measurement of IgG-MUC1-CIC using C595
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Measurement of IgM-MUC1-CIC
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Measurement of SM3 antibody
Number of subjects: 70
Study: 10970043

Group type: EXPERIMENTAL
Intervention: US treated wine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated white wine (CON)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: US treated wine (in rabbits)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated wine (CON) (in rabbits)
Number of subjects: 0
Study: 9252011

Group type: EXPERIMENTAL
Intervention: Pain sensation intensity
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Pain unpleasantness (stage 1 affect)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Suffering (stage 2 affect)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Pain behavior
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Confirmatory LISREL analysis
Number of subjects: 506
Study: 1735489

Group type: EXPERIMENTAL
Intervention: Uterine transfer
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tubal embryo transfer (ET)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Uterine transfers
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tubal ETs
Number of subjects: 42
Study: 6366769

Group type: EXPERIMENTAL
Intervention: Penicillin therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 35
Study: 31429355

Group type: EXPERIMENTAL
Intervention: Diet modification program with increased intake of lactose, fiber, magnesium, zinc, B3, and B5; lower intake of glucose and lipid.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Diet modification program
Number of subjects: 170
Study: 31327314

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 607
Study: 29031771

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (24 hours/week, maximum caloric intake of 300 kcal on fasting days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (maintained habitual nutrition)
Number of subjects: 36
Study: 27007018

Group type: EXPERIMENTAL
Intervention: Oral Impact
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 25375826

Group type: EXPERIMENTAL
Intervention: Intervention in skills of control, stimulus recognition, and phonological awareness over a 4-month period for RD+ASF group.
Number of subjects: 280

Group type: COMPARATOR
Intervention: Intervention in skills of control, stimulus recognition, and phonological awareness over a 4-month period for RD group.
Number of subjects: 280

Group type: COMPARATOR
Intervention: Intervention in skills of control, stimulus recognition, and phonological awareness over a 4-month period for RL group.
Number of subjects: 280
Study: 22503654

Group type: EXPERIMENTAL
Intervention: Combined counseling and progressive resistance home-exercises
Number of subjects: 108

Group type: COMPARATOR
Intervention: Counseling, balance-training and support from the physical therapist (Control group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Both groups (Intervention and Control)
Number of subjects: 108
Study: 19858141

Group type: EXPERIMENTAL
Intervention: Active treatment (antihypertensive medication)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16965225

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) monotherapy 500 mg twice daily in slow running infusion for twelve days followed by oral administration of 500 mg twice daily until delivery
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) monotherapy 3x250 mg daily
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combined therapy of UDCA and SAMe
Number of subjects: 78
Study: 14653123

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study: 11009047

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg b.i.d.) with mirtazapine (30 mg nocte)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with mirtazapine (30 mg nocte)
Number of subjects: 12
Study: 9611400

Group type: EXPERIMENTAL
Intervention: Neonatal TSH values in Salazie
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Prevalence of goiter
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Median urinary iodine levels
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Intake of milk and dairy products
Number of subjects: 294
Study: 8406286

Group type: EXPERIMENTAL
Intervention: Etofibrat
Number of subjects: 55

Group type: COMPARATOR
Intervention: Other lipid-lowering agents
Number of subjects: 55

Group type: COMPARATOR
Intervention: No further medication
Number of subjects: 55
Study: 2949396

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg b.i.d. for 14 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo b.i.d. for 14 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy males (matched age)
Number of subjects: 25
Study: 31712838

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Palpation-guided corticosteroid injection
Number of subjects: 44
Study: 30226342

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/kg/h)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 52
Study: 28230732

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich blueberry drink
Number of subjects: 71

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 71
Study: 26634183

Group type: EXPERIMENTAL
Intervention: Porcine small intestine submucosa (SIS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 82
Study: 24289490

Group type: EXPERIMENTAL
Intervention: Tutored PBL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tutorless PBL
Number of subjects: 0
Study: 21074212

Group type: EXPERIMENTAL
Intervention: Index tumor volume threshold of 0.5 ml
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Index tumor volume threshold after accounting for tumor stage and grade
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Total tumor volume threshold
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Total tumor volume threshold after accounting for tumor stage and grade
Number of subjects: 325
Study: 20552850

Group type: EXPERIMENTAL
Intervention: Chewing gum three times per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucking on hard candy three times per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17233236

Group type: EXPERIMENTAL
Intervention: Nicotine gum in combination with counseling (motivational interviewing or health education)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo gum in combination with counseling (motivational interviewing or health education)
Number of subjects: 755
Study: 15731509

Group type: EXPERIMENTAL
Intervention: Aban Aya Youth Project
Number of subjects: 552

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 552
Study: 12789991

Group type: EXPERIMENTAL
Intervention: Colgate Simply White Clear Whitening Gel (18% carbamide peroxide)
Number of subjects: 141
Study: 9798802

Group type: EXPERIMENTAL
Intervention: Trospium chloride (1.2 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Biperiden (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study: 7636454

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan (6 mg per dose, one or two doses for a single migraine episode)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 648

Group type: COMPARATOR
Intervention: Aspirin and Acetaminophen
Number of subjects: 648
Study: 2197532

Group type: EXPERIMENTAL
Intervention: 300 mg pentamidine in 6 ml Aqua dest. with Inspiratory vital capacity breathing
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Portasonic nebulizer
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 600 mg pentamidine in 6 ml Aqua dest.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulization
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Inspiratory vital capacity breathing (12/min)
Number of subjects: 6
Study: 318710

Group type: EXPERIMENTAL
Intervention: Methadyl acetate, dispensed three times per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone, dispensed six days per week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methadyl acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 0
Study: 31081480

Group type: EXPERIMENTAL
Intervention: dual‐disorder treatment of PTSD and SUD using prolonged exposure
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: single‐disorder relapse prevention treatment for SUD
Number of subjects: 107

Group type: COMPARATOR
Intervention: active monitoring control group
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: African Americans compared to Whites
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Religious affiliation
Number of subjects: 107
Study: 27880052

Group type: EXPERIMENTAL
Intervention: Ultrasound guided BoNT‐A injections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electromyographic guided BoNT‐A injections
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 25987410

Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) stimulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Left ventricular (LV) stimulation
Number of subjects: 28
Study: 23768769

Group type: EXPERIMENTAL
Intervention: Large defect width
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Large defect length
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Large defect area
Number of subjects: 865
Study: 21885549

Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase (3 cycles of 250,000 U)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (pleural drainage only)
Number of subjects: 47
Study: 19345145

Group type: EXPERIMENTAL
Intervention: TK-cells infused starting 28 days after transplantation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TK-cells infusion
Number of subjects: 50
Study: 16679277

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA
Number of subjects: 45

Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 45

Group type: COMPARATOR
Intervention: Gd-DOTA
Number of subjects: 45
Study: 15292468

Group type: EXPERIMENTAL
Intervention: Behavioral condition
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study: 11177331

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin once daily (1.5 mg/kg)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin twice daily (1.0 mg/kg)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 900
Study: 9541762

Group type: EXPERIMENTAL
Intervention: Pharmacologic management of angina
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Pharmacologic management of angina and ambulatory ECG evidence of ischemia
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Revascularization (angioplasty and coronary artery bypass surgery)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 558
Study: 7889194

Group type: EXPERIMENTAL
Intervention: TCV-116 at 4 mg/day for 4 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups during arithmetic stress
Number of subjects: 8
Study: 2663263

Group type: EXPERIMENTAL
Intervention: Magnesium aspartate (10 mmol/day) for 8 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 4612057

Group type: EXPERIMENTAL
Intervention: 15 mg morphine intravenously
Number of subjects: 69
Study: 30815695

Group type: EXPERIMENTAL
Intervention: Air velocity at the feeder: 1, 2, and 3 m/s
Number of subjects: 216

Group type: COMPARATOR
Intervention: Air velocity at the feeder: 0 m/s (control)
Number of subjects: 216
Study: 28495265

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 5 cm of water pressure
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: CPAP in children younger than 1 year
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Control in children younger than 1 year
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: CPAP in children aged up to 6 months
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: CPAP in children aged 12 months
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: CPAP in children aged 24 months
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: CPAP in children aged 36 months
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2200
Study: 25106891

Group type: EXPERIMENTAL
Intervention: GnRHa therapy (1.2 mg daily as nasal spray for 4 weeks before and 4 weeks after surgery)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Orchiopexy alone
Number of subjects: 62
Study: 22185951

Group type: EXPERIMENTAL
Intervention: Cell salvage group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 18272539

Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum VRI-003 (PCC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18808628

Group type: EXPERIMENTAL
Intervention: Complete silver yoga with stretching and meditation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Shortened silver yoga without guided-imagery meditation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 204
Study: 16100298

Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Darifenacin 75 mg
Number of subjects: 188

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 12047487

Group type: EXPERIMENTAL
Intervention: Sustained release paracetamol (SR paracetamol), 4 g/day (two 665 mg tablets taken three times daily)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Immediate release paracetamol (IR paracetamol), 4 g/day (two 500 mg tablets taken four times daily)
Number of subjects: 403
Study: 15321150

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 21

Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 21
Study: 7555167

Group type: EXPERIMENTAL
Intervention: Autogenic drainage (AD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Postural drainage with clapping (PD)
Number of subjects: 10
Study: 2259925

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate
Number of subjects: 0
Study: 7032826

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg three times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Captopril (200 mg three times a day) + Placebo
Number of subjects: 20
Study: 31679812

Group type: EXPERIMENTAL
Intervention: Monthly group visits sessions (n=55)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual care (n=54)
Number of subjects: 109
Study: 31488369

Group type: EXPERIMENTAL
Intervention: Intervention group (n=644)
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Control group (n=727)
Number of subjects: 1371
Study: 27885470

Group type: EXPERIMENTAL
Intervention: Transforaminal endoscopic discectomy (TED)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Microdiscectomy (Micro)
Number of subjects: 143
Study: 25450709

Group type: EXPERIMENTAL
Intervention: Besifovir 90 mg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Besifovir 150 mg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Entecavir 0.5 mg
Number of subjects: 89
Study: 23337964

Group type: EXPERIMENTAL
Intervention: Aloe vera
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chamomilla recutita
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Melissa officinalis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Melaleuca alternifolia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coriandrum sativum
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate
Number of subjects: 40

Group type: COMPARATOR
Intervention: unguentum leniens
Number of subjects: 40
Study: 21226966

Group type: EXPERIMENTAL
Intervention: Facilitated program of evidence awareness, access to tailored research evidence, critical appraisal skills development, networking and evidence summaries
Number of subjects: 28

Group type: COMPARATOR
Intervention: Provision of evidence summaries alone
Number of subjects: 28
Study: 19742332

Group type: EXPERIMENTAL
Intervention: Nasogastric decompression group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-nasogastric decompression group
Number of subjects: 108
Study: 16732214

Group type: EXPERIMENTAL
Intervention: Local anaesthesia with propofol sedation and sub-Tenon's anaesthesia (lidocaine/mercaine infusion)
Number of subjects: 32

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 32
Study: 16945619

Group type: EXPERIMENTAL
Intervention: Diet mixer (225 kcal)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Regular mixer (478 kcal)
Number of subjects: 8
Study: 14674622

Group type: EXPERIMENTAL
Intervention: Ultrasonography measurements of fetal biparietal diameter (BPD), abdominal circumference (AC), and femur length (FL)
Number of subjects: 710
Study: 10028206

Group type: EXPERIMENTAL
Intervention: Group therapy for 20 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Quasi-experimental control group
Number of subjects: 40